<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689673</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-58216-001</org_study_id>
    <nct_id>NCT03689673</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)</brief_title>
  <official_title>A Prospective, Multicenter, Non-interventional Study to Describe the Effectiveness of Etiasa® (Sustained Release Granules of Mesalazine or 5-Aminosalicylate, or 5-ASA) in Maintenance Treatment of Ulcerative Colitis (UC )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol is to assess the effectiveness of Etiasa® for preventing relapse
      in Chinese patients with quiescent UC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to relapse according to the patients with different maintenance Etiasa® daily dose</measure>
    <time_frame>Until relapse or maximum 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rates at 5 years or at study termination according to different maintenance Etiasa® daily dose</measure>
    <time_frame>5 years or at study termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin change from baseline to each hospital visit and relapse</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin change from baseline to each hospital visit and relapse</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) change from baseline to each hospital visit and relapse</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate (ESR) change from baseline to each hospital visit and relapse</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6) change from baseline to each hospital visit and relapse</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colorectal cancer (CRC) incidence rate</measure>
    <time_frame>Until relapse or maximum 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) changes during the treatment</measure>
    <time_frame>From baseline until relapse or 5 years or early termination</time_frame>
    <description>Assessed by Inflammatory Bowel Disease Questionnaire (IBDQ) a health-related quality of life (HRQoL) tool measuring physical, social, and emotional status (score 10-70, poor to good HRQoL).</description>
  </secondary_outcome>
  <enrollment type="Actual">622</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patient ≥ 18 years old and ≤ 65 years old

          -  Patient has provided written informed consent to participate in the study after the
             purpose and nature have been clearly explained to him/her;

          -  Patient with documented diagnosis of mild-moderate Ulcerative Colitis (UC). The
             &quot;documented diagnosis&quot; should include a typical histology observed at least once in
             the course of the disease;

          -  Have a documented history of UC that has been successfully maintained in complete
             steroid-free remission for at least 1 month prior to study entry;

          -  The modified mayo score ≤ 2, without subscore &gt;1, which is supported by a
             rectum-sigmoidoscopy or a colonoscopy;

          -  Regimen of maintenance of remission contains Etiasa®

          -  Patient mentally and physically able to answer the questionnaire.

        Exclusion Criteria:

          -  Have a history of allergy or hypersensitivity to salicylates, 5-aminosalicylates, or
             any component of Etiasa®;

          -  Pregnant and breastfeeding women, approaching childbirth female or unwilling to take
             birth control measures during the study;

          -  A topical 5-aminosalicylate agent is included in the regimen;

          -  Patients with infectious colitis (positive for germs, ovum or parasites causing bowel
             disease);

          -  Treated with the other study drug at enrollment, or within past 3 months of
             enrollment;

          -  Serious underlying disease other than UC which in the opinion of the investigator may
             interfere with the patient's ability to participate fully in the study;

          -  Crohn's disease;

          -  Pancreatitis;

          -  Known bleeding disorders;

          -  Potentially unreliable patients, and those judged by the investigator to be unsuitable
             for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated Beijing Chao-yang Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of The Third Military Medical University of Chinese PLA</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yatsen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yatsen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebi People Hospital</name>
      <address>
        <city>Hebi</city>
        <zip>450018</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Province People Hospital</name>
      <address>
        <city>Henan</city>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The PLA 150 Central Hospital</name>
      <address>
        <city>Luoyang</city>
        <zip>471031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated hospital of Nan Chang University</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Command</name>
      <address>
        <city>Nanjing</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of TCM</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <zip>266034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzhou Third People Hospital</name>
      <address>
        <city>Suzhou</city>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated to Tongji Medical College</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of the Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

